UNSPSC 51284708: Distamycin a or stallimycin

This classification denotes a distamycin antibiotic and dna minor groove binding agent with the molecular formula C22H27N9O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80O63P88IS, chemically known as distamycin a, hydrochloride but generally known as distamycin a, which bears US NIH Compound Identifier 3115. European Medicines Agency schedules Stallimycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10640MIG. The term DISTAMYCIN A is an International Non-Proprietary Name.

Distamycin a or stallimycin bears US NLM identifiers UMLS ID C0244119 and NCI Concept Code C1517. SMILES: O=C(NC1CC(N(C1)C)C(=O)NCCC(=N)N)C1N(CC(NC(=O)C2N(CC(NC=O)C2)C)C1)C.

UNSPSC 51284708 Distamycin a or stallimycin, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The two most recent opportunities tagged under this code involve pharmaceutical procurement but do not reflect the specific antimicrobial agents named in the code. The Illinois Department of Public Health awarded a completed piggyback contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, for supply of Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets totaling $2,999,999.11 over a three-year term. Seminole County, Florida issued an IFB on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the county's Community Health Building. Neither opportunity involves distamycin a or stallimycin procurement, suggesting the code has been misapplied or sees limited state and local buying activity in the pharmaceutical market under its specific classification.

The geographic footprint reflected in recent activity spans Florida and Illinois, with both opportunities tied to public health agencies. The issuing bodies include a state health department and a county health authority, both pursuing pharmaceutical and medical supply acquisition through cooperative purchasing vehicles and competitive bidding. No repeat buyers or sustained procurement patterns under this code are evident in the recent opportunity record. Vendors pursuing work under this code should verify whether opportunities are accurately classified and consider monitoring broader pharmaceutical supply and antimicrobial procurement codes where state and local health agencies show more consistent buying activity.